Godrej Agrovet FY26: Revenue ₹10,232.68 cr, up 9%

What triggered attention on Godrej Agrovet

Godrej Agrovet Ltd. (GAVL) drew market attention after it responded to a BSE query on reports linked to an expansion of its crop protection business portfolio and distribution networks. The company said it is fully compliant with SEBI regulations and that it has not withheld any material information. In parallel, the company’s financial disclosures for FY26 and recent quarters show a mix of full-year growth and quarterly fluctuations. The FY26 print indicated revenue crossing the ₹10,000 crore mark, while Q4 revenue fell sequentially versus Q3. For investors tracking the agribusiness cycle, this combination of regulatory clarification and operating numbers is typically watched closely.

BSE inquiry: what the company said

In its communication to the exchange, Godrej Agrovet addressed the news flow around crop protection expansion. The company stated that it is in compliance with applicable SEBI regulations and that there is no undisclosed material information. This response matters because exchange queries often arise when price or volume action coincides with media reports, and companies are required to confirm whether there is any information that should be disclosed. Based on the company’s stated position, investors have to rely on reported financials and disclosed business commentary rather than assuming a corporate action is pending.

FY26 snapshot: revenue, profit, and EPS

For FY26, Godrej Agrovet reported revenue of ₹10,232.68 crore, compared with ₹9,382.77 crore in FY25, a 9.06% year-on-year increase. Profit after tax (PAT) for FY26 stood at ₹445.18 crore, compared with ₹403.37 crore in FY25, up 10.36% year-on-year. EPS for FY26 was reported at ₹24.58 versus ₹22.35 in FY25, an increase of 9.98% year-on-year. These full-year figures indicate that growth was not only top-line led, but also reflected in reported earnings.

Q4 FY26: sequential revenue decline, YoY growth

Quarterly revenue numbers show a different pattern. Q4 revenue was ₹2,332.65 crore, compared with ₹2,718.32 crore in Q3, implying a 14.21% QoQ decrease. However, Q4 revenue was higher than ₹2,133.64 crore in Q4 FY25, reflecting a 9.33% YoY increase. This combination suggests Q4 remained ahead of the year-ago base but did not sustain Q3’s run-rate. Investors typically interpret such swings in the context of seasonal demand, commodity-linked realizations, and segment-level volatility.

Q3 FY26: revenue growth and margin metrics

For Q3 FY26, the company reported revenue around ₹2,718 crore with year-on-year growth of 11% to ₹2,718 crore from ₹2,450 crore (as presented in one summary table). EBITDA was disclosed at ₹260 crore versus ₹229 crore, up 13.6%, with EBITDA margin at 9.6% versus 9.3%. Profit before tax (PBT) was ₹169 crore compared with ₹138 crore, up 23.1%. Reported PAT numbers in the provided disclosures vary by presentation: one table shows PAT ₹110 crore (flat year-on-year), another summary states PAT ₹133 crore versus ₹99 crore, and a separate data snapshot lists net profit ₹114.82 crore.

Segment-led drivers mentioned for Q3

Operational commentary for Q3 highlighted performance across Animal Feed, Vegetable Oil, and Crop Protection. Animal Feed volumes were reported up 12.00% to 445,060 MT; segment revenue rose 1.90% to ₹1,298 crore, while underlying segment result improved 16.90% to ₹90 crore. The Vegetable Oil segment reported revenue growth of 27.00% to ₹618 crore, with segment result up 25.20% to ₹144 crore and margin cited at 23.40%. Crop Protection was shown at +37.20% to ₹136 crore, alongside a note on weather-related margin challenges. ASTEC Lifesciences was described as turning profitable in Q3 FY26, with revenue ₹125 crore (up 32.9%) and EBITDA ₹5 crore versus a loss of ₹4 crore in Q3 FY25.

Dividend, earnings date, and investor information

The disclosures also reference shareholder-facing updates. Godrej Agrovet declared a dividend of ₹11.00 per share on 31 Jul, 2025. An upcoming earnings date is listed as 3rd Feb, 2026. The company’s investor relations coverage is described as including GAVL share price, annual reports, financials, and shareholder information for investors across India.

Stock and balance-sheet signals cited in the data

A price snapshot included in the provided text put the stock at ₹548.65 as of Feb 03, 2026. Over the prior year, it showed a return of -27.62%, compared with the Sensex at 8.49%. On leverage, the debt-to-equity ratio for the half-year period was cited at 1.19 times. The same dataset listed operating margin (excluding other income) at 8.90% for Q3 FY26 and PAT margin at 4.04%, with sequential improvement but a year-on-year contraction.

Key numbers table

Why this update matters for investors

Two threads are relevant in this news flow. First, the BSE clarification reduces the risk of investors anchoring expectations on unconfirmed business expansion developments in crop protection. Second, the financial picture shows full-year growth in revenue, PAT, and EPS, but also quarter-to-quarter variability, with Q4 revenue dropping from Q3 even while remaining higher than the year-ago quarter. For valuation and sentiment, the cited one-year stock return of -27.62% alongside leverage of 1.19x debt-to-equity are datapoints investors may weigh against segment momentum and margin commentary.

Conclusion

Godrej Agrovet’s FY26 numbers show revenue of ₹10,232.68 crore and PAT of ₹445.18 crore, while quarterly trends show a Q4 revenue decline versus Q3. The company’s response to BSE stated there is no undisclosed material information on the reported crop protection expansion theme. The next widely tracked milestone referenced in the disclosures is the 3 Feb, 2026 earnings date, alongside ongoing investor communications through the company’s IR channels.